Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The metabolic syndrome (MetS) is a well described cluster of interrelated risk factors for developing cardiovascular disease and type 2 diabetes. The key components of MetS are central obesity, hypertension, hyperglycaemia and dyslipidaemia. The 2005 International Diabetes Federation (IDF) consensus definition of MetS aimed to reduce confusion over criteria for MetS and to provide a simple diagnostic and clinical tool. There is considerable evidence to show that patients prescribed antipsychotic drugs are at increased risk of developing MetS. Existing clinical guidelines for metabolic screening of patients taking antipsychotics focus on diabetes rather than on the broader syndrome of MetS and are not consistent with the IDF definition of MetS. Monitoring for MetS in patients taking antipsychotics (both inpatients and outpatients) is generally poor. We present a user-friendly clinical algorithm and monitoring form, based on current evidence and using the IDF definition of MetS, to help clinicians in primary care or specialist settings to effectively monitor for MetS in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness and efficiency of guideline dissemination and implementation strategies
Grimshaw, J., Thomas, R., MacLennan, G., Fraser, C., Ramsay, C., Vale, L., Whitty, P., Eccles, M., Matowe, L., Shirran, L., et al. (2004) · Health Technology Assessment · doi:10.3310/hta8060 · Cited by 3,044
Stern, M. P., Williams, K., González-Villalpando, C., Hunt, K. J., & Haffner, S. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2676 · Cited by 735
Cited by
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
“Over recent years, both national and international groups have developed screening and monitoring guidelines [5,10,22, 31,34,42,48,90,115,133,137] but these are not being routinely implemented in the clinical care of patients [20,63,87,99], although they appear to be cost-effective [19].”
BackgroundDE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870
Kisely, S., Campbell, L. A., & Wang, Y. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067082 · Cited by 116
McEachin, R. C., Saccone, N. L., Saccone, S. F., Kleyman-Smith, Y. D., Kar, T., Kare, R. K., Ade, A. S., Sartor, M. A., Cavalcoli, J. D., & McInnis, M. G. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-14 · Cited by 31
“Consistent with this observation, many genes that are expressed in the brain are expressed in other tissues, so variation that influences psychiatric disorders may have whole body effects and influence what are traditionally considered medical disorders [88-90], thus blurring the boundaries between psychiatric and med…”
BackgroundGiusti, L., Bianchini, V., Aggio, A., Mammarella, S., Salza, A., Necozione, S., Alunno, A., Ferri, C., Casacchia, M., & Roncone, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.903759 · Cited by 6
Metadata
- Authors
- Waterreus, A. J., & Laugharne, J. D. E.
- Venue
- Medical Journal of Australia
- Publisher
- AMPCo
- Published
- 2009-02
- Volume
- 190
- Issue
- 4
- Pages
- 185-189
- ISSN
- 0025-729X (ISSN-L)
- 1326-5377
- OpenAlex
- W2124630195
- Cited by
- 54
- References
- 2
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. https://app.cochat.ai/papers/10.5694/j.1326-5377.2009.tb02344.x
- The paper
- Waterreus, A. J., & Laugharne, J. D. E. (2009). Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2009.tb02344.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.